This page has information about the PSA test – a blood test that can help diagnose prostate problems, including prostate cancer. We explain who can have a PSA test, what will happen if you have a test, and what your PSA results might mean.

There are advantages and disadvantages to having a PSA test. You’ll need to talk to your GP or practice nurse about these before deciding whether to have one.

We know that some men have trouble getting a PSA test and have included suggestions for what to do if this happens.

What is the PSA blood test?

The PSA test is a blood test that measures the amount of prostate specific antigen (PSA) in your blood. PSA is a protein produced by normal cells in the prostate and also by prostate cancer cells. It’s normal to have a small amount of PSA in your blood, and the amount rises slightly as you get older and your prostate gets bigger. A raised PSA level may suggest you have a problem with your prostate, but not necessarily cancer.

gp

Understanding the PSA blood test booklet

This booklet is for men who are thinking about having a PSA test. 

Download or order booklet

Who can have a PSA blood test?

You have the right to a PSA test if you’re over 50 and you’ve thought carefully about the advantages and disadvantages. If you’re Black or you have a family history of prostate cancer, it can also increase your risk – so you may want to speak to your GP about having a PSA test from the age of 45.

You may also be offered a PSA test if you have symptoms of a possible prostate problem.

Some men are offered a PSA test as part of a general check-up. You should still think about the advantages and disadvantages and whether the test is right for you before agreeing to have one.

What could affect my PSA level?

Prostate problems, such as an enlarged prostateprostatitis or prostate cancer, can cause your PSA level to rise – but lots of other things can affect your PSA level too, including the following.

  • A urine infection – You may have a test for a urine infection as this can raise your PSA level. If you have an infection, you’ll be given treatment for it. You’ll need to wait until the infection has gone – around six weeks – before you have a PSA test.
  • Vigorous exercise – Activities that raise your heart rate like cycling may raise your PSA level for a few days. So it's a good idea to avoid vigorous exercise for 48 hours before the blood test.
  • Ejaculation – You should avoid any sexual activity that leads to ejaculation in the 48 hours before a PSA blood test.
  • Anal sex and prostate stimulation – Receiving anal sex, or having your prostate stimulated during sex, might raise your PSA level for a while. You should avoid this for a week before a PSA test.
  • Prostate biopsy – If you’ve had a biopsy in the six weeks before a PSA test, this could raise your PSA level.
  • Medicines – Let your GP or practice nurse know if you’re taking any prescription or over-the-counter medicines, as some might affect your PSA level. For example, some medicines used to treat an enlarged prostate, known as 5-alpha-reductase inhibitors such as finasteride (Proscar®) or dutasteride (Avodart®), can reduce your PSA level and give a false test result.
  • Other tests or surgery – If you've had any tests or surgery on your bladder or prostate, you may need to wait up to six weeks before having a PSA test.
  • Urinary catheters – If you have a catheter to drain urine from your bladder, you may need to wait up to six weeks after it has been put in before having a PSA test.

Having a PSA blood test

You can have a PSA test at your GP surgery. Your GP or practice nurse might talk to you about having a PSA test if you're worried about prostate problems, if you’re at increased risk of getting prostate cancer, or if you have symptoms such as problems urinating.

What will happen at the GP surgery?

If you don't have any symptoms, your GP or practice nurse should talk to you about the advantages and disadvantages of the PSA test before you decide whether to have one. You should tell them if anyone in your family has had prostate or breast cancer.

Your GP or practice nurse will also talk to you about your general health and any other health problems. If you have a serious health problem that means you wouldn't be fit enough for treatment for prostate cancer, or if treatment wouldn’t help you to live longer, your GP may not recommend having a PSA test unless you have symptoms of a possible prostate problem.

If you decide you want a PSA test, your GP may also talk to you about a digital rectal examination (DRE) and a urine test to rule out a urine infection. A DRE is usually only needed if you have symptoms. You don’t have to have a DRE. You can choose to have a PSA blood test alone.

What does the PSA blood test involve?

A sample of your blood is taken and sent to a laboratory to be tested. The amount of PSA in your blood is measured in nanograms (a billionth of a gram) per millilitre of blood (ng/ml). You can eat and drink as normal before having a PSA test.

It can take one to two weeks to get your test results.

PSA blood testing in the community

PSA tests are available to all men over 50 for free from their GP. You may sometimes see PSA tests being offered in places such as community centres or football stadiums.  If you’re thinking about having a PSA test at this type of event, make sure a doctor or nurse will be there to give you information and support.

If you can, it’s usually best to visit your GP for a PSA test. If you do have a PSA test in the community you should inform your GP surgery so they can add the result to your records, which are seen by your GP. If you’re unsure or worried about your result, speak to your GP.

PSA blood testing at home

PSA blood tests and urine tests for other men’s health conditions can be bought online. These home tests may not be accurate and reliable, and it is best to get any tests you want through your GP instead. They will be able to explain the results and answer any other questions you have too.

What will the test results tell me?

Lots of things can cause a raised PSA level, including the following prostate problems:

So a PSA test alone can’t usually tell you if you have prostate cancer. It's the first step in deciding if you need more tests, including an MRI scan

To decide whether you need to see a specialist at the hospital, your GP will look at:

What is a normal PSA level?

For many men, normal PSA levels are usually less than 3ng/ml. But this will vary from person to person and depends on a lot of things including:

  • your age
  • your general health
  • if you have any urinary symptoms
  • if you are on any medication.

Your doctor will tell you what your own PSA level should be.

What happens next?

If your doctor thinks your PSA level is high, they may refer you to a specialist at a hospital for more tests. You will usually see a specialist within a few weeks.

If your GP thinks something else has caused your PSA level to be raised, they might suggest having another PSA test in the future to see if your PSA level changes, rather than seeing a specialist straight away. You can also ask your GP to refer you to a specialist.

Your GP should discuss all of this with you, to help you decide what to do next.

My PSA was a little high, so my GP referred me to a specialist for more tests.
A personal experience

Regular PSA blood tests

After some men have had their first PSA test they might want to have regular tests every few years, particularly if they have an increased risk of prostate cancer. This might be a good way to spot any changes in your PSA level that might suggest prostate cancer. But we need more research to show how often you might need a test. You could discuss this with your GP or practice nurse, or call our Risk Information Service.

You can order a PSA card to keep a record of your PSA level.

Advantages and disadvantages of the PSA blood test

It’s important to think through the advantages and disadvantages of the PSA test. Having a PSA test is a personal decision – what might be important to one man may be less important to another.

Advantages

  • It can help pick up prostate cancer before you have any symptoms.
  • It can help pick up a fast-growing cancer at an early stage, when treatment could stop it spreading and causing problems.
  • A regular PSA test could be helpful, particularly if you have an increased risk of prostate cancer. This could detect any unusual increase in your PSA level that might be a sign of prostate cancer.

Disadvantages

  • Your PSA level might be raised, even if you don’t have prostate cancer. Many men with a raised PSA level don’t have prostate cancer.
  • The PSA test can miss prostate cancer. For example, one major study showed that 1 in 7 men with a normal PSA level may have prostate cancer, and 1 in 50 men with a normal PSA level may have a fast-growing cancer.
  • If your PSA level is raised you may need a biopsy. This can cause side effects, such as pain, infection and bleeding. But most men now have an MRI scan first, and only have a biopsy if the scan finds anything unusual.
  • Being diagnosed with a slow-growing prostate cancer that is unlikely to cause any problems or shorten your life may still make you worry, and may lead you to have treatment that you don't need. But most men with low-risk, localised prostate cancer now have their cancer carefully monitored instead, and only have treatment if the cancer starts to grow. 

Should I have a PSA blood test?

Deciding whether or not to have a PSA test can be difficult. Before you decide, try asking yourself the following questions, or discuss them with your GP or practice nurse.

  • Am I at increased risk of prostate cancer?
  • If my PSA level was normal, would this reassure me?
  • What would happen if my PSA level was higher than expected?
  • If I was diagnosed with slow-growing prostate cancer that might never cause any problems, would I still want to have treatment, even though it could cause side effects? Or would I be comfortable having my cancer monitored instead?

It might help to talk this over with your partner, family or friends. If you want to discuss the test, call our Risk Information Service. Our staff can help you understand your own risk of prostate cancer and talk you through the advantages and disadvantages of the PSA test.

You may also find it helpful to fill out this information sheet. It has space to write down any risk factors or symptoms you have and lists questions you might want to ask your GP.

You could have the sheet in front of you when you talk to your GP, to help guide your conversation.

Worried about going to the GP?

If you’re worried about your risk of prostate cancer or have any unusual symptoms, it's important to speak to your GP.

It’s natural to feel worried or embarrassed about going to the doctor or having tests. But don’t let that stop you going to your GP. Remember, the tests give your GP the best idea about whether you have a problem that needs treating.

My GP explained the PSA test and its limitations. He told me the decision was mine and suggested I think it over, talk to my partner, and come back if I wanted one.
A personal experience

What if my GP won't give me a PSA blood test?

You have the right to a PSA test if you’re over 50 and you’ve thought carefully about the pros and cons. If you then decide that you want a test, your GP should give you one.

A PSA test isn't suitable for everyone. For example, your GP may not recommend it if your general health means you wouldn't be fit enough for treatment for prostate cancer, or if treatment wouldn't help you to live longer.

If your GP doesn't agree to do a PSA test, ask them to explain why, as there may be a good reason.

Explain that you are entitled to a PSA test under the NHS Prostate Cancer Risk Management Programme. It might help to print this webpage and take it to the appointment with you. You could also print and show them our information for GPs.

  • If they still say no, try speaking to another GP or practice nurse.
  • If they also say no, speak to the practice manager at your GP surgery.
  • Your GP surgery should have information about its complaints procedure. You can follow this procedure, or write to the GP or practice manager explaining your complaint.

If you still can't get a PSA test, you could follow the NHS complaints procedure.

  • In England: you can complain to NHS England. The NHS website has more information.
  • In Scotland: you can complain to your local health board. The Patient Advice and Support Service can provide information, advice and support. Get more information from NHS Inform.
  • In Wales: you can complain to your local health board. Your local Community Health Council can help with this. Health in Wales has more information.
  • In Northern Ireland: you can complain to the Northern Ireland Public Services Ombudsman. Get more information from nidirect.

Make sure you include the following information in your complaint:

  • your name
  • your contact details – such as your home address, telephone number or email address
  • a clear description of your complaint – including what happened, where and when
  • details of any relevant conversations, letters or emails you’ve had.

You can also get advice and support from Citizens Advice.

If you’re not sure whether to make a complaint, get in touch with our Risk Information Service. We can help you understand your risk of prostate cancer so that you can decide what to do next.

Why isn't there a prostate cancer screening programme?

There is currently no screening programme for prostate cancer in the UK and you will not be invited for a PSA test by your GP.

Screening programmes aim to find early signs of cancer in people who don’t yet have any symptoms. They invite all suitable people to have a test to find out if they are at risk. In the UK there are screening programmes for breast, cervical, bowel and lung cancer. Finding cancer early means it could be treated in time to get rid of it before it causes any problems.

It’s important that the benefits of any screening programme outweigh the disadvantages. But it isn’t clear that screening all men with the PSA test would have more benefits than disadvantages.

Some studies have found that screening with the PSA test could mean fewer men die from prostate cancer. But it would also mean that:

  • some men would have a biopsy, which could cause side effects
  • a large number of men would be diagnosed with a slow-growing cancer that wouldn’t cause any symptoms or shorten their life
  • some of these men would have treatment they didn’t need, which could cause side effects.

While the PSA test on its own isn't suitable as a screening test for prostate cancer, our TRANSFORM clinical trial will help to find a test, or combination of tests, that could make screening possible in the future.

Until then, the Prostate Cancer Risk Management Programme gives men over 50 the right to have a PSA test on the NHS – as long as they’ve thought carefully about the advantages and disadvantages.

References and reviewers

Updated January 2025 | Due for Review: January 2027

  • Office for Health Improvement and Disparities. Advising men without symptoms of prostate disease who ask about the PSA test [Internet]. 2022 [cited 2024 May 7]. Available from: https://www.gov.uk/government/publications/prostate-specific-antigen-testing-explanation-and-implementation/advising-well-men-about-the-psa-test-for-prostate-cancer-information-for-gps
  • Prostate Cancer UK. Interim position on the PSA blood test in asymptomatic men [Internet]. 2022. Available from: https://prostatecanceruk.org/for-health-professionals/guidelines/interim-position-on-the-psa-blood-test-in-asymptomatic-men
  • National Institute for Health and Care Excellence. Suspected cancer: recognition and referral [Internet]. 2023. Available from: https://www.nice.org.uk/guidance/ng12
  • Gaglani S, Purohit RS, Tewari AK, Kyprianou N, Lundon DJ. Embryologic and hormonal contributors to prostate cancer in transgender women. Am J Clin Exp Urol. 2022;10:63–72.
  • Manfredi C, Ditonno F, Franco A, Bologna E, Licari LC, Arcaniolo D, et al. Prostate Cancer in Transgender Women: Epidemiology, Clinical Characteristics, and Management Challenges. Curr Oncol Rep [Internet]. 2023 [cited 2023 Nov 7]; Available from: https://link.springer.com/10.1007/s11912-023-01470-w
  • de Nie I, de Blok CJM, van der Sluis TM, Barbé E, Pigot GLS, Wiepjes CM, et al. Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment. J Clin Endocrinol Metab. 2020;105:e3293–9.
  • National Institute for Health and Care Excellence. Lower urinary tract symptoms in men: management. 2015;26.
  • National Institute for Health and Care Excellence. 2019 surveillance of ‘Lower urinary tract symptoms in men: management’ (NICE guideline CG97). 2019.
  • Dobrek L. Lower Urinary Tract Disorders as Adverse Drug Reactions—A Literature Review. Pharmaceuticals. 2023;16:1031.
  • Kirby M, Chapple C, Jackson G, Eardley I, Edwards D, Hackett G, et al. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract. 2013;67:606–18.
  • Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK: Burden of male LUTS suggestive of BPH. BJU Int. 2015;115:508–19.
  • Acute prostatitis - Symptoms, diagnosis and treatment | BMJ Best Practice [Internet]. 2024 [cited 2024 Apr 8]. Available from: https://bestpractice.bmj.com/topics/en-gb/172?q=Prostatitis&c=suggested
  • Engeler D, Baranowski AP, Berghmans B, Birch J, Borovicka J, Cottrell A, et al. EAU Guidelines on Chronic Pelvic Pain [Internet]. European Association of Urology; 2024 [cited 2024 Jun 3]. Available from: https://uroweb.org/guidelines/chronic-pelvic-pain
  • BMJ. BMJ Best Practice: Acute prostatitis [Internet]. 2022 [cited 2022 Oct 31]. Available from: https://bestpractice.bmj.com/topics/en-gb/172/pdf/172/Acute%20prostatitis.pdf
  • Coker TJ, Dierfeldt DM. Acute Bacterial Prostatitis: Diagnosis and Management. Am Fam Physician. 2016;93:114–20.
  • National Institute for Health and Care Excellence. Prostatitis - chronic [Internet]. 2022. Available from: https://cks.nice.org.uk/topics/prostatitis-chronic/
  • Benelli A, Hossain H, Pilatz A, Weidner W. Prostatitis and its Management. Eur Urol Suppl. 2017;16:132–7.
  • Cancer Research UK. Cancer incidence for common cancers [Internet]. [cited 2024 May 7]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/common-cancers-compared#heading-One
  • Cancer Research UK. Prostate cancer incidence statistics [Internet]. [cited 2024 May 7]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Four
  • National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management [Internet]. 2021 [cited 2022 Dec 19]. Available from: https://www.nice.org.uk/guidance/ng131
  • Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388:1547–58.
  • Cancer Research UK. Prostate cancer incidence statistics: by age (2014-2016) [Internet]. 2019. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-One
  • Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010. BMC Med. 2015;13:171.
  • Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review. Eur Urol. 2023;84:191–206.
  • COONEY KA. Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact. Trans Am Clin Climatol Assoc. 2017;128:14–23.
  • Beebe-Dimmer JL, Kapron AL, Fraser AM, Smith KR, Cooney KA. Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. J Clin Oncol. 2020;38:1807–13.
  • Tzenios N, Tazanios ME, Chahine M. The impact of body mass index on prostate cancer: An updated systematic review and meta-analysis. Medicine (Baltimore). 2022;101:e30191.
  • Harrison S, Tilling K, Turner EL, Martin RM, Lennon R, Lane JA, et al. Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer Causes Control. 2020;31:431–49.
  • Rivera-Izquierdo M, Pérez De Rojas J, Martínez-Ruiz V, Arrabal-Polo MÁ, Pérez-Gómez B, Jiménez-Moleón JJ. Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients. Prostate Cancer Prostatic Dis. 2022;25:411–21.
  • Aaron L, Franco O, Hayward S. Review of Prostate Anatomy and Embryology and the Etiology of BPH. Urol Clin North Am. 2016;43:279–88.
  • Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int. 2008;102:1400–6.
  • Tarhan F, Orçun A, Küçükercan I, Camursoy N, Kuyumcuoğlu U. Effect of prostatic massage on serum complexed prostate-specific antigen levels. Urology. 2005;66:1234–8.
  • Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, et al. Use of 5- -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol. 2009;27:1502–16.
  • Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology; 2022.
  • Javaeed A, Ghauri SK, Ibrahim A, Doheim MF. Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review. Oncol Rev. 2020;14:449.
  • Neal DE, et al. DE. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. Eur Urol [Internet]. 2019 [cited 2022 Feb 2]; 
  • Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet. 2017;
  • Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med [Internet]. 2018 [cited 2018 May 4]; Available from: http://www.nejm.org/doi/10.1056/NEJMoa1801993
  • Schieda N, Maralani PJ, Hurrell C, Tsampalieros AK, Hiremath S. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists. Can Assoc Radiol J. 2019;70:226–32.
  • Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69:16–40.
  • Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;
  • Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016;
  • Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P. EAU Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism. European Association of Urology; 2019.
  • Cornford P, Tilki D, Van Den Bergh RCN, Briers E. EAU Guidelines on Prostate Cancer [Internet]. European Association of Urology; 2024 [cited 2024 May 16]. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024_2024-04-09-132035_ypmy_2024-04-16-122605_lqpk.pdf
  • Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter. N Engl J Med. 2004;350:2239–46.
  • Kilpeläinen TP, Tammela TLJ, Roobol M, Hugosson J, Ciatto S, Nelen V, et al. False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer. 2011;47:2698–705.
  • Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ. 2012;344:d7894.
  • Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876–92.
  • How to complain to the NHS [Internet]. [cited 2019 Jul 29]. Available from: https://www.nhs.uk/using-the-nhs/about-the-nhs/how-to-complain-to-the-nhs/
  • NHS Scotland complaints [Internet]. [cited 2019 Jul 29]. Available from: https://www.nhsinform.scot/care-support-and-rights/health-rights/feedback-and-complaints/nhs-scotland-complaints
  • Board of Community Health Councils. Board of Community Health Councils - NHS Complaints procedure - how we can help [Internet]. [cited 2019 Jul 29]. Available from: http://www.wales.nhs.uk/sitesplus/899/page/71619
  • Press Office D for H. Make a complaint against the health service | nidirect [Internet]. 2008 [cited 2019 Jul 29]. Available from: http://www.nidirect.gov.uk/make-a-complaint-against-the-health-service
  • Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;12.
  • Tesfai A, Norori N, Harding TA, Wong YH, Hobbs MD. Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review. BJUI Compass. 2024;bco2.326.
  • Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. The Lancet. 2014;384:2027–35.

This publication has been reviewed for accuracy and updated by: 

  • Karen Wilkinson, Uro-Oncology Clinical Nurse Specialist, University College London Hospital
  • Declan Cahill, Consultant Urologist, Royal Marsden Hospital
  • Jonathan Rees, General Practitioner
  • Our Specialist Nurses
  • Our volunteers